TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25251396

Group type: EXPERIMENTAL
Intervention: Mastery goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance-approach goals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative feedback (for any task type)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative feedback for the rule-finding task
Number of subjects: 0
Study: 21707770

Group type: EXPERIMENTAL
Intervention: Educational intervention for self-management
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 64
Study: 20071147

Group type: EXPERIMENTAL
Intervention: Haloperidol (n=23)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Risperidone (n=93)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Olanzapine (n=57)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall treatment response
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Catatonia signs
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Convergent validity of DSM-IV catatonia signs
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Concordance of DSM-IV criteria
Number of subjects: 200
Study: 17646216

Group type: EXPERIMENTAL
Intervention: Repeated sit‐to‐stands using a GrandStand System
Number of subjects: 66

Group type: COMPARATOR
Intervention: Knee extensions using ankle cuff weights (Control)
Number of subjects: 66
Study: 15701470

Group type: COMPARATOR
Intervention: Atrioventricular conventional pacing (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atriobiventricular pacing (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crossover to atrioventricular conventional pacing (after initial 3 months of atrio-biventricular pacing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crossover back to atrio-biventricular pacing (after initial 3 months of atrioventricular conventional pacing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal pacing therapy
Number of subjects: 0
Study: 12075254

Group type: EXPERIMENTAL
Intervention: Ventricular rate control
Number of subjects: 4060

Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 4060
Study: 10207960

Group type: EXPERIMENTAL
Intervention: Hydrogel (Coloplast), n = 17
Number of subjects: 32

Group type: COMPARATOR
Intervention: Wet saline compresses, n = 15
Number of subjects: 32
Study: 7499006

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg b.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg q.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: 14-hydroxy metabolite with 500 mg q.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 14-hydroxy metabolite with 250 mg b.i.d.
Number of subjects: 12
Study: 1933049

Group type: EXPERIMENTAL
Intervention: Caffeine alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caffeine plus smoking
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo plus smoking
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 15
Study: 6786895

Group type: EXPERIMENTAL
Intervention: Cimetidine 0.8 g daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31993753

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (OC) - cooling the mouth with ice for ≥ 30 minutes during chemotherapy infusions.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no oral cryotherapy).
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (OC).
Number of subjects: 53
Study: 30685420

Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation (12.4 mmol NO3− per day for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation
Number of subjects: 12
Study: 27208923

Group type: EXPERIMENTAL
Intervention: SFO + LEU (4.2 g of leucine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SFO + ALA (4.2 g of alanine)
Number of subjects: 18
Study: 25280603

Group type: EXPERIMENTAL
Intervention: Kyrobak (Radiancy, Hod-hasharon, Israel) self-treatment for 10 minutes, one to three times per day, for 3 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Kyrobak (Radiancy, Hod-hasharon, Israel) self-treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waiting-list control (WLC) group
Number of subjects: 36
Study: 23528101

Group type: EXPERIMENTAL
Intervention: rFVIII-FS prophylaxis (25 IU kg(‐1), three times weekly)
Number of subjects: 84

Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 84
Study: 21900595

Group type: COMPARATOR
Intervention: Alcohol intake levels of 3.4 g/d or less
Number of subjects: 41836

Group type: COMPARATOR
Intervention: Alcohol intake levels of more than 3.4 g/d
Number of subjects: 41836

Group type: COMPARATOR
Intervention: Alcohol intake levels of 30 g/d or less
Number of subjects: 41836

Group type: COMPARATOR
Intervention: Alcohol intake levels of more than 30 g/d
Number of subjects: 41836

Group type: COMPARATOR
Intervention: Alcohol intake levels by quartile distributions
Number of subjects: 41836

Group type: COMPARATOR
Intervention: Alcohol intake levels and MSI-, CIMP-, or BRAF-defined CRC subtypes
Number of subjects: 41836
Study: 19143021

Group type: EXPERIMENTAL
Intervention: Fractional radiofrequency (FRF) treatment using Renesis device, delivering RF energy at 72 degrees C for 4 seconds.
Number of subjects: 0
Study: 17589656

Group type: EXPERIMENTAL
Intervention: Salivary stimulation (group 1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Chlorhexidine mouth rinses (group 2)
Number of subjects: 31
Study: 15231555

Group type: EXPERIMENTAL
Intervention: Computerised cognitive-behavioural therapy (CBT)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 274
Study: 12359854

Group type: EXPERIMENTAL
Intervention: BSE instruction group
Number of subjects: 266064

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 266064
Study: 9842383

Group type: EXPERIMENTAL
Intervention: Soil lead abatement (replacement of contaminated soil with clean soil)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (no soil lead abatement)
Number of subjects: 187
Study: 8205873

Group type: EXPERIMENTAL
Intervention: Portable monitoring using MESAM 4
Number of subjects: 349
Study: 2683452

Group type: EXPERIMENTAL
Intervention: Prospective studies in orthopedics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical studies in orthopedics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test statistics in orthopedic studies
Number of subjects: 0
Study: 370042

Group type: EXPERIMENTAL
Intervention: 600 mg of supplementary vitamin C daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 42
Study: 30382496

Group type: EXPERIMENTAL
Intervention: Sequential practice schedule
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Success orientation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Time-only goal
Number of subjects: 40
Study: 28077734

Group type: COMPARATOR
Intervention: 1 egg/d
Number of subjects: 38

Group type: COMPARATOR
Intervention: 2-3 eggs/d
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3 eggs/d
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0 eggs/d
Number of subjects: 38
Study: 26094093

Group type: EXPERIMENTAL
Intervention: Karydakis flap (K-flap)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Excision with healing by secondary intention (EHSI)
Number of subjects: 321
Study: 23494898

Group type: EXPERIMENTAL
Intervention: Guided Disclosure Protocol (GDP) - writing about the patient's diagnosis and treatment for 15 minutes a day over 3 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control - writing about what the patient did the previous day for 15 minutes a day over 3 days
Number of subjects: 102
Study: 22180357

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/d, n = 47)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d, n = 45)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 134
Study: 19691482

Group type: COMPARATOR
Intervention: Tirofiban (50 ng mL(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PSI-697 (low-dose 2 m)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PSI-697 (high-dose 20 m)
Number of subjects: 12
Study: 17378888

Group type: EXPERIMENTAL
Intervention: Vector fluid polish (VU-H)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supragingival polishing (PO-H)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hand instruments (HI-H) performed by a hygienist
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hand instruments (HI-D) performed by a dentist
Number of subjects: 20
Study: 15142020

Group type: EXPERIMENTAL
Intervention: Sand surface (S condition)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Wood surface (F condition)
Number of subjects: 16
Study: 11468942

Group type: EXPERIMENTAL
Intervention: Mizolastine pediatric solution (0.15 mg/kg once daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mizolastine pediatric solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reference population design with 10 samples per child
Number of subjects: 60
Study: 9694025

Group type: EXPERIMENTAL
Intervention: Clonidine 200 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7832669

Group type: EXPERIMENTAL
Intervention: MRC-MOPD method
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard insemination methods
Number of subjects: 29
Study: 2856549

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study: 31847733

Group type: EXPERIMENTAL
Intervention: Convex optimization‐based interactive segmentation approach
Number of subjects: 46
Study: 30247714

Group type: EXPERIMENTAL
Intervention: Protein supplementation (21 g protein, 3 g total leucine, 9 g carbohydrate, 3 g fat; n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (0 g protein, 25 g carbohydrate, 6 g fat; n = 20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 28643799

Group type: EXPERIMENTAL
Intervention: Aflibercept treatment initiated for nAMD
Number of subjects: 5620
Study: 26632710

Group type: EXPERIMENTAL
Intervention: Quadruple therapy based on E‐test results (rabeprazole + bismuth potassium citrate + amoxicillin + clarithromycin) for 14 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Empirical therapy (rabeprazole + bismuth potassium citrate + amoxicillin + clarithromycin)
Number of subjects: 90
Study: 25098068

Group type: EXPERIMENTAL
Intervention: Single dose antibiotic before inguinal hernia mesh repair
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo before inguinal hernia mesh repair
Number of subjects: 166
Study: 22030224

Group type: EXPERIMENTAL
Intervention: Palm olein (PO) diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Coconut oil (CO) diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Virgin olive oil (OO) diet
Number of subjects: 45
Study: 18351203

Group type: EXPERIMENTAL
Intervention: Supracrestal gingival tissue measurements
Number of subjects: 100
Study: 17030771

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study: 14687438

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10-40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: atorvastatin 10-80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: simvastatin 10-80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: pravastatin 10-40 mg
Number of subjects: 0
Study: 10750679

Group type: EXPERIMENTAL
Intervention: Prenatal employment
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: History of prenatal employment
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Intention to work after delivery
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 171
Study: 9042739

Group type: EXPERIMENTAL
Intervention: Nonverbal auditory stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal stimuli in conjunction with visual information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal-visual combination
Number of subjects: 0
Study: 1525588

Group type: EXPERIMENTAL
Intervention: Radioiodine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 4025299

Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) in usual care
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) in special intervention
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) overall
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) in usual care (adjusted)
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) in special intervention (adjusted)
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) overall (adjusted)
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Jenkins Activity Survey Type A score
Number of subjects: 3110
Study: 30225903

Group type: EXPERIMENTAL
Intervention: Dual regimen (low-fluence stamping mode at 5-6 J/cm2 followed by moving mode)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional high-fluence stamp mode (14-15 J/cm2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dual regimen
Number of subjects: 24
Study: 26777722

Group type: EXPERIMENTAL
Intervention: Aquatic aerobic training (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dry-land aerobic training (n = 18)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Aquatic aerobic training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dry-land aerobic training
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 24791618

Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22931394

Group type: EXPERIMENTAL
Intervention: Ice pack applied for 10 minutes
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Ice pack applied for 15 minutes
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ice pack applied for 20 minutes (historical control)
Number of subjects: 114
Study: 20124953

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with MPA-AUC less than 30 mg hr/L
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with MPA-AUC more than or equal to 30 mg hr/L
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with MPA-AUC less than 30 mg hr/L in tacrolimus-treated patients
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with MPA-AUC more than or equal to 30 mg hr/L in tacrolimus-treated patients
Number of subjects: 549

Group type: COMPARATOR
Intervention: Mycophenolate mofetil in low-risk patients
Number of subjects: 549
Study: 18612571

Group type: EXPERIMENTAL
Intervention: Advice (brief intervention)
Number of subjects: 575

Group type: COMPARATOR
Intervention: No advice (control)
Number of subjects: 575
Study: 16796276

Group type: EXPERIMENTAL
Intervention: 70 mg alendronate once weekly
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 335

Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 335
Study: 12709133

Group type: EXPERIMENTAL
Intervention: Three-dimensional relative colour histogram analysis technique using percent melanoma colour feature.
Number of subjects: 258
Study: 10723850

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 8694320

Group type: EXPERIMENTAL
Intervention: Digital pressure during interscalene block
Number of subjects: 20

Group type: COMPARATOR
Intervention: No digital pressure during interscalene block
Number of subjects: 20
Study: 1360032

Group type: EXPERIMENTAL
Intervention: Routine doppler ultrasound examinations of the umbilical and uterine arteries during pregnancy (first at 19-22 weeks, then monthly for high risk or once at 32 weeks for low risk)
Number of subjects: 2475

Group type: EXPERIMENTAL
Intervention: Standard antenatal care with routine doppler examinations
Number of subjects: 2475

Group type: COMPARATOR
Intervention: Standard antenatal care without doppler ultrasonography
Number of subjects: 2475
Study: 6146153

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study: 31298705

Group type: EXPERIMENTAL
Intervention: Decreased mammographic density (MD) over time
Number of subjects: 43810

Group type: COMPARATOR
Intervention: Stable mammographic density (MD)
Number of subjects: 43810

Group type: COMPARATOR
Intervention: Increasing mammographic density (MD)
Number of subjects: 43810
Study: 30791819

Group type: EXPERIMENTAL
Intervention: QuinteT Recruitment Intervention (QRI)
Number of subjects: 0
Study: 28235424

Group type: EXPERIMENTAL
Intervention: BMMSC group
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: BMMNC group
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (Bobath therapy)
Number of subjects: 105
Study: 30641621

Group type: EXPERIMENTAL
Intervention: Chinese medicine group (CM) - Astragalus Granule (AG)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined group - Astragalus Granule (AG) and auricular point sticking
Number of subjects: 150

Group type: COMPARATOR
Intervention: Western medicine group (WM) - Basic treatment with aerosol inhalation (Budesonide suspension and Terbutaline Sulphate Solution)
Number of subjects: 150
Study: 23723319

Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine (HPV16/18), administered at 0, 1, and 6 months
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine (HPV16/18)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy controls (not vaccinated)
Number of subjects: 68
Study: 22019331

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 μg, 2 doses per week for 48 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study: 19436116

Group type: EXPERIMENTAL
Intervention: pilsicainide (150 mg/day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: bepridil (200 mg/day)
Number of subjects: 59
Study: 17263861

Group type: EXPERIMENTAL
Intervention: Rectal Voltarol
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 210

Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 210
Study: 15194570

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11529382

Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg/day) for 10 days after initial ceftriaxone (75 mg/kg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ceftriaxone (75 mg/kg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg/day)
Number of subjects: 36
Study: 9779032

Group type: EXPERIMENTAL
Intervention: Enoxaparin and ticlopidine
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 123
Study: 8142127

Group type: EXPERIMENTAL
Intervention: 10% sucralfate suspension (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antacid containing sodium alginate (Group 1)
Number of subjects: 80
Study: 3203571

Group type: EXPERIMENTAL
Intervention: 30 g of fructose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isocaloric amount of starch (control)
Number of subjects: 8
Study: 30075198

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 282

Group type: COMPARATOR
Intervention: Therapeutic normothermia
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Severe AKI
Number of subjects: 282
Study: 27620342

Group type: EXPERIMENTAL
Intervention: EXER (exercise program)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: EXER + CBT (exercise program plus cognitive-behavioral therapy)
Number of subjects: 66

Group type: COMPARATOR
Intervention: CONTROL (routine treatment)
Number of subjects: 66
Study: 25780837

Group type: EXPERIMENTAL
Intervention: Rural patients receiving surgical treatment for hip osteoarthritis
Number of subjects: 200

Group type: COMPARATOR
Intervention: Urban patients receiving surgical treatment for hip osteoarthritis
Number of subjects: 200
Study: 24326918

Group type: EXPERIMENTAL
Intervention: Rubric exam preparation group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nonrubric exam preparation group
Number of subjects: 65
Study: 21353262

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (beer, ∼26 g alcohol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alcohol-free beer (control)
Number of subjects: 24
Study: 19767761

Group type: EXPERIMENTAL
Intervention: 16 G-needle
Number of subjects: 187

Group type: COMPARATOR
Intervention: 18 G-needle
Number of subjects: 187
Study: 16790200

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab bolus
Number of subjects: 137

Group type: COMPARATOR
Intervention: Intravenous abciximab bolus
Number of subjects: 137
Study: 15884481

Group type: EXPERIMENTAL
Intervention: Reduced-frequency prenatal visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy (group prenatal care)
Number of subjects: 0
Study: 11141361

Group type: EXPERIMENTAL
Intervention: Smears
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Cultures
Number of subjects: 139
Study: 9118185

Group type: EXPERIMENTAL
Intervention: F dentifrice (0.145% F as NaF) only
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: F dentifrice + F lozenges (0.25 mg F x 6/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: F dentifrice + F chewing-gum (0.25 mg F x 6/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (F dentifrice only)
Number of subjects: 12
Study: 8397836

Group type: EXPERIMENTAL
Intervention: Colgate Precision Full Head soft toothbrush
Number of subjects: 72

Group type: COMPARATOR
Intervention: Crest Complete soft toothbrush
Number of subjects: 72
Study: 3538481

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (20 mg thrice daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13